Pathobiologic mechanisms of chronic obstructive pulmonary disease

Medical Clinics of North America

Volumn 96, Issue 4, 2012, Pages 681-698

  Tam, Anthony ^a   Sin, Don D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cigarette smoke; COPD; Immunity; Inflammation; Pathobiologic mechanism

Indexed keywords

B7 ANTIGEN; CARCINOGEN; CD86 ANTIGEN; CIGARETTE SMOKE; CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DIMETHYLNITROSAMINE; EPIDERMAL GROWTH FACTOR; FIBRONECTIN; FORMALDEHYDE; GELATINASE A; GELATINASE B; GRANZYME; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE ELASTASE; MUCIN 5AC; MYELOID DIFFERENTIATION FACTOR 88; NICOTINE; PERFORIN; PROTEINASE; PROTEINASE INHIBITOR; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; AUTOIMMUNITY; BIOMASS; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; COUGHING; DISEASE COURSE; EMPHYSEMA; FORCED VITAL CAPACITY; GENE EXPRESSION; GOBLET CELL; HUMAN; HYPERCAPNIA; HYPOTHESIS; HYPOXEMIA; INNATE IMMUNITY; MUCUS SECRETION; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RESPIRATORY TRACT INFECTION; REVIEW; SQUAMOUS CELL METAPLASIA;

ADAPTIVE IMMUNITY; AIRWAY REMODELING; BIOLOGICAL MARKERS; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE PROGRESSION; EMPHYSEMA; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; MODELS, BIOLOGICAL; MUCUS; PEPTIDE HYDROLASES; PHENOTYPE; PROTEASE INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SMOKING;

EID: 84863814792     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.04.012     Document Type: Review

References (124)

1. Barnes P.J., Shapiro S.D., Pauwels R.A. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003, 22(4):672-688.
2. Lopez A.D., Murray C.C. The global burden of disease, 1990-2020. Nat Med 1998, 4(11):1241-1243.
3. Mackay J., Eriksen M., Shafey O. The tobacco atlas 2006, American Cancer Society, Atlanta (GA).
4. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995, 152(5 Pt 2):S77-S121.
5. Barnes P.J. Chronic obstructive pulmonary disease. N Engl J Med 2000, 343(4):269-280.
6. Snider G.L. Chronic obstructive pulmonary disease: a definition and implications of structural determinants of airflow obstruction for epidemiology. Am Rev Respir Dis 1989, 140(3 Pt 2):S3-S8.
7. Rennard S.I. COPD: overview of definitions, epidemiology, and factors influencing its development. Chest 1998, 113(Suppl 4):235S-241S.
8. Hogg J.C., Chu F.S., Tan W.C., et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med 2007, 176(5):454-459.
9. Hogg J.C., Chu F., Utokaparch S., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350(26):2645-2653.
10. Tashkin D.P., Altose M.D., Connett J.E., et al. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am J Respir Crit Care Med 1996, 153(6 Pt 1):1802-1811.
11. Matsuba K., Thurlbeck W.M. The number and dimensions of small airways in emphysematous lungs. Am J Pathol 1972, 67(2):265-275.
12. Friedlander A.L., Lynch D., Dyar L.A., et al. Phenotypes of chronic obstructive pulmonary disease. COPD 2007, 4(4):355-384.
13. Patel B.D., Coxson H.O., Pillai S.G., et al. Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 178(5):500-505.
14. Gosselink J.V., Hayashi S., Elliott W.M., et al. Differential expression of tissue repair genes in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010, 181(12):1329-1335.
15. Kitaguchi Y., Fujimoto K., Kubo K., et al. Characteristics of COPD phenotypes classified according to the findings of HRCT. Respir Med 2006, 100(10):1742-1752.
16. Papaioannou A.I., Mazioti A., Kiropoulos T., et al. Systemic and airway inflammation and the presence of emphysema in patients with COPD. Respir Med 2010, 104(2):275-282.
17. McDonough J.E., Yuan R., Suzuki M., et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 2011, 365(17):1567-1575.
18. General U.S. The health consequences of smoking: chronic obstructive lung disease 1984, US Gov Press Office, Rockville (MD).
19. Ding Y.S., Zhang L., Jain R.B., et al. Levels of tobacco-specific nitrosamines and polycyclic aromatic hydrocarbons in mainstream smoke from different tobacco varieties. Cancer Epidemiol Biomarkers Prev 2008, 17(12):3366-3371.
20. Ben-Zaken Cohen S., Pare P.D., Man S.F., et al. The growing burden of chronic obstructive pulmonary disease and lung cancer in women: examining sex differences in cigarette smoke metabolism. Am J Respir Crit Care Med 2007, 176(2):113-120.
21. Denissenko M.F., Pao A., Tang M., et al. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996, 274(5286):430-432.
22. Hecht S.S. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 1998, 11(6):559-603.
23. Hukkanen J., Jacob P., Benowitz N.L. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005, 57(1):79-115.
24. Benowitz N.L., Jacob P. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther 1994, 56(5):483-493.
25. Dix T.A., Marnett L.J. Metabolism of polycyclic aromatic hydrocarbon derivatives to ultimate carcinogens during lipid peroxidation. Science 1983, 221(4605):77-79.
26. Wilson A.S., Davis C.D., Williams D.P., et al. Characterisation of the toxic metabolite(s) of naphthalene. Toxicology 1996, 114(3):233-242.
27. Guengerich F.P. Cytochrome P450: what have we learned and what are the future issues?. Drug Metab Rev 2004, 36(2):159-197.
28. Hulbert W.C., Walker D.C., Jackson A., et al. Airway permeability to horseradish peroxidase in guinea pigs: the repair phase after injury by cigarette smoke. Am Rev Respir Dis 1981, 123(3):320-326.
29. Fels A.O., Cohn Z.A. The alveolar macrophage. J Appl Physiol 1986, 60(2):353-369.
30. Macklin C.C. Pulmonary sumps, dust accumulations, alveolar fluid and lymph vessels. Acta Anat (Basel) 1955, 23(1):1-33.
31. Knowles M.R., Boucher R.C. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002, 109(5):571-577.
32. Green G.M., Jakab G.J., Low R.B., et al. Defense mechanisms of the respiratory membrane. Am Rev Respir Dis 1977, 115(3):479-514.
33. Simani A.S., Inoue S., Hogg J.C. Penetration of the respiratory epithelium of guinea pigs following exposure to cigarette smoke. Lab Invest 1974, 31(1):75-81.
34. Jones J.G., Minty B.D., Lawler P., et al. Increased alveolar epithelial permeability in cigarette smokers. Lancet 1980, 1(8159):66-68.
35. Malhotra S., Man S.F., Sin D.D. Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs 2006, 11(2):275-291.
36. Doz E., Noulin N., Boichot E., et al. Cigarette smoke-induced pulmonary inflammation is TLR4/MyD88 and IL-1R1/MyD88 signaling dependent. J Immunol 2008, 180(2):1169-1178.
37. Imler J.L., Hoffmann J.A. Toll receptors in innate immunity. Trends Cell Biol 2001, 11(7):304-311.
38. Aderem A., Ulevitch R.J. Toll-like receptors in the induction of the innate immune response. Nature 2000, 406(6797):782-787.
39. Sha Q., Truong-Tran A.Q., Plitt J.R., et al. Activation of airway epithelial cells by toll-like receptor agonists. Am J Respir Cell Mol Biol 2004, 31(3):358-364.
40. Liu A.N., Mohammed A.Z., Rice W.R., et al. Perforin-independent CD8(+) T-cell-mediated cytotoxicity of alveolar epithelial cells is preferentially mediated by tumor necrosis factor-alpha: relative insensitivity to Fas ligand. Am J Respir Cell Mol Biol 1999, 20(5):849-858.
41. Keatings V.M., Collins P.D., Scott D.M., et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996, 153(2):530-534.
42. Kilburn K.H. A hypothesis for pulmonary clearance and its implications. Am Rev Respir Dis 1968, 98(3):449-463.
43. Hovenberg H.W., Davies J.R., Carlstedt I. Different mucins are produced by the surface epithelium and the submucosa in human trachea: identification of MUC5AC as a major mucin from the goblet cells. Biochem J 1996, 318(Pt 1):319-324.
44. Thornton D.J., Rousseau K., McGuckin M.A. Structure and function of the polymeric mucins in airways mucus. Annu Rev Physiol 2008, 70:459-486.
45. Smirnova M.G., Guo L., Birchall J.P., et al. LPS up-regulates mucin and cytokine mRNA expression and stimulates mucin and cytokine secretion in goblet cells. Cell Immunol 2003, 221(1):42-49.
46. Yoon J.H., Kim K.S., Kim H.U., et al. Effects of TNF-alpha and IL-1 beta on mucin, lysozyme, IL-6 and IL-8 in passage-2 normal human nasal epithelial cells. Acta Otolaryngol 1999, 119(8):905-910.
47. Chen Y., Thai P., Zhao Y.H., et al. Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J Biol Chem 2003, 278(19):17036-17043.
48. Danahay H., Atherton H., Jones G., et al. Interleukin-13 induces a hypersecretory ion transport phenotype in human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2002, 282(2):L226-L236.
49. Voynow J.A., Young L.R., Wang Y., et al. Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells. Am J Physiol 1999, 276(5 Pt 1):L835-L843.
50. Takeyama K., Dabbagh K., Lee H.M., et al. Epidermal growth factor system regulates mucin production in airways. Proc Natl Acad Sci U S A 1999, 96(6):3081-3086.
51. Shao M.X., Nakanaga T., Nadel J.A. Cigarette smoke induces MUC5AC mucin overproduction via tumor necrosis factor-alpha-converting enzyme in human airway epithelial (NCI-H292) cells. Am J Physiol Lung Cell Mol Physiol 2004, 287(2):L420-L427.
52. Kohri K., Ueki I.F., Shim J.J., et al. Pseudomonas aeruginosa induces MUC5AC production via epidermal growth factor receptor. Eur Respir J 2002, 20(5):1263-1270.
53. Choi H.J., Chung Y.S., Kim H.J., et al. Signal pathway of 17beta-estradiol-induced MUC5B expression in human airway epithelial cells. Am J Respir Cell Mol Biol 2009, 40(2):168-178.
54. Monick M.M., Yarovinsky T.O., Powers L.S., et al. Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. J Biol Chem 2003, 278(52):53035-53044.
55. Hasday J.D., Bascom R., Costa J.J., et al. Bacterial endotoxin is an active component of cigarette smoke. Chest 1999, 115(3):829-835.
56. Vlahos R., Bozinovski S., Jones J.E., et al. Differential protease, innate immunity, and NF-kappaB induction profiles during lung inflammation induced by subchronic cigarette smoke exposure in mice. Am J Physiol Lung Cell Mol Physiol 2006, 290(5):L931-L945.
57. Dekhuijzen P.N. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 2004, 23(4):629-636.
58. Asea A., Rehli M., Kabingu E., et al. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 2002, 277(17):15028-15034.
59. Vayssier M., Banzet N., Francois D., et al. Tobacco smoke induces both apoptosis and necrosis in mammalian cells: differential effects of HSP70. Am J Physiol 1998, 275(4 Pt 1):L771-L779.
60. Pace E., Ferraro M., Siena L., et al. Cigarette smoke increases Toll-like receptor 4 and modifies lipopolysaccharide-mediated responses in airway epithelial cells. Immunology 2008, 124(3):401-411.
61. Kulkarni R., Rampersaud R., Aguilar J.L., et al. Cigarette smoke inhibits airway epithelial cell innate immune responses to bacteria. Infect Immun 2010, 78(5):2146-2152.
62. Bagaitkar J., Demuth D.R., Scott D.A. Tobacco use increases susceptibility to bacterial infection. Tob Induc Dis 2008, 4:12.
63. Drannik A.G., Pouladi M.A., Robbins C.S., et al. Impact of cigarette smoke on clearance and inflammation after Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2004, 170(11):1164-1171.
64. El Ahmer O.R., Essery S.D., Saadi A.T., et al. The effect of cigarette smoke on adherence of respiratory pathogens to buccal epithelial cells. FEMS Immunol Med Microbiol 1999, 23(1):27-36.
65. Hodge S., Hodge G., Ahern J., et al. Smoking alters alveolar macrophage recognition and phagocytic ability: implications in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2007, 37(6):748-755.
66. Sayers N.M., Drucker D.B. Animal models used to test the interactions between infectious agents and products of cigarette smoked implicated in sudden infant death syndrome. FEMS Immunol Med Microbiol 1999, 25(1-2):115-123.
67. Sorensen L.T., Nielsen H.B., Kharazmi A., et al. Effect of smoking and abstention on oxidative burst and reactivity of neutrophils and monocytes. Surgery 2004, 136(5):1047-1053.
68. Baqir M., Chen C.Z., Martin R.J., et al. Cigarette smoke decreases MARCO expression in macrophages: implication in Mycoplasma pneumoniae infection. Respir Med 2008, 102(11):1604-1610.
69. Nouri-Shirazi M., Tinajero R., Guinet E. Nicotine alters the biological activities of developing mouse bone marrow-derived dendritic cells (DCs). Immunol Lett 2007, 109(2):155-164.
70. Robbins C.S., Franco F., Mouded M., et al. Cigarette smoke exposure impairs dendritic cell maturation and T cell proliferation in thoracic lymph nodes of mice. J Immunol 2008, 180(10):6623-6628.
71. Niewoehner D.E., Kleinerman J., Rice D.B. Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med 1974, 291(15):755-758.
72. Fletcher C., Peto R. The natural history of chronic airflow obstruction. Br Med J 1977, 1(6077):1645-1648.
73. Churg A., Zay K., Shay S., et al. Acute cigarette smoke-induced connective tissue breakdown requires both neutrophils and macrophage metalloelastase in mice. Am J Respir Cell Mol Biol 2002, 27(3):368-374.
74. Hogg J.C., Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 2009, 4:435-459.
75. Rennard S.I. Cigarette smoke in research. Am J Respir Cell Mol Biol 2004, 31(5):479-480.
76. Hackett T.L., Shaheen F., Johnson A., et al. Characterization of side population cells from human airway epithelium. Stem Cells 2008, 26(10):2576-2585.
77. Chen H., Matsumoto K., Stripp B.R. Bronchiolar progenitor cells. Proc Am Thorac Soc 2009, 6(7):602-606.
78. Knight D.A., Holgate S.T. The airway epithelium: structural and functional properties in health and disease. Respirology 2003, 8(4):432-446.
79. Paulsson M. Basement membrane proteins: structure, assembly, and cellular interactions. Crit Rev Biochem Mol Biol 1992, 27(1-2):93-127.
80. Horiba K., Fukuda Y. Synchronous appearance of fibronectin, integrin alpha 5 beta 1, vinculin and actin in epithelial cells and fibroblasts during rat tracheal wound healing. Virchows Arch 1994, 425(4):425-434.
81. Rickard K.A., Taylor J., Rennard S.I., et al. Migration of bovine bronchial epithelial cells to extracellular matrix components. Am J Respir Cell Mol Biol 1993, 8(1):63-68.
82. Sirianni F.E., Milaninezhad A., Chu F.S., et al. Alteration of fibroblast architecture and loss of basal lamina apertures in human emphysematous lung. Am J Respir Crit Care Med 2006, 173(6):632-638.
83. Van Der Geld Y.M., Van Straaten J.F., Postma D.S., et al. Role of proteoglycans in development and pathogenesis of emphysema. Proteoglycans in lung disease 2002, 241-267. Marcel Dekker, New York. H.G. Garg, P.J. Roughly, C.A. Hales (Eds.).
84. Zandvoort A., Postma D.S., Jonker M.R., et al. Altered expression of the Smad signalling pathway: implications for COPD pathogenesis. Eur Respir J 2006, 28(3):533-541.
85. Springer J., Scholz F.R., Peiser C., et al. SMAD-signaling in chronic obstructive pulmonary disease: transcriptional down-regulation of inhibitory SMAD 6 and 7 by cigarette smoke. Biol Chem 2004, 385(7):649-653.
86. National Heart, Lung, and Blood Institute Morbidity and mortality: 2000 chartbook on cardiovascular, lung, and blood diseases 2000, US Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda (MD).
87. Orie N.G.M., Sluiter H.J., de Vries K., et al. The host factor in bronchitis. Bronchitis 1961, 43-59. Royal van Gorcum, Assen (The Netherlands). N.G.M. Orie, H.J. Sluiter (Eds.).
88. Silverman E.K., Palmer L.J., Mosley J.D., et al. Genomewide linkage analysis of quantitative spirometric phenotypes in severe early-onset chronic obstructive pulmonary disease. Am J Hum Genet 2002, 70(5):1229-1239.
89. Hospers J.J., Postma D.S., Rijcken B., et al. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet 2000, 356(9238):1313-1317.
90. Vestbo J., Edwards L.D., Scanlon P.D., et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011, 365(13):1184-1192.
91. Postma D.S., Kerkhof M., Boezen H.M., et al. Asthma and chronic obstructive pulmonary disease: common genes, common environments?. Am J Respir Crit Care Med 2011, 183(12):1588-1594.
92. Barnes P.J. Against the Dutch hypothesis: asthma and chronic obstructive pulmonary disease are distinct diseases. Am J Respir Crit Care Med 2006, 174(3):240-243. [discussion: 243-4].
93. Barnes P.J., Ito K., Adcock I.M. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004, 363(9410):731-733.
94. Fletcher C.M. Chronic bronchitis. Its prevalence, nature, and pathogenesis. Am Rev Respir Dis 1959, 80:483-494.
95. Kanner R.E., Anthonisen N.R., Connett J.E. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med 2001, 164(3):358-364.
96. Donaldson G.C., Seemungal T.A., Bhowmik A., et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002, 57(10):847-852.
97. Wilkinson T.M., Patel I.S., Wilks M., et al. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 167(8):1090-1095.
98. Sethi S., Evans N., Grant B.J., et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002, 347(7):465-471.
99. Hurst J.R., Vestbo J., Anzueto A., et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363(12):1128-1138.
100. Rennard S.I. Chronic obstructive pulmonary disease: linking outcomes and pathobiology of disease modification. Proc Am Thorac Soc 2006, 3(3):276-280.
101. Soriano J.B., Agusti A. The yin and yang of COPD: or balancing repair (yang) and inflammation (yin). Eur Respir J 2008, 32(6):1426-1427.
102. Man S.F., Xing L., Connett J.E., et al. Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD?. Eur Respir J 2008, 32(6):1451-1457.
103. Stockley R.A. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med 1999, 160(5 Pt 2):S49-S52.
104. Sommerhoff C.P., Nadel J.A., Basbaum C.B., et al. Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. J Clin Invest 1990, 85(3):682-689.
105. Witko-Sarsat V., Halbwachs-Mecarelli L., Schuster A., et al. Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum. Am J Respir Cell Mol Biol 1999, 20(4):729-736.
106. Shapiro S.D., Senior R.M. Matrix metalloproteinases. Matrix degradation and more. Am J Respir Cell Mol Biol 1999, 20(6):1100-1102.
107. Finlay G.A., O'Driscoll L.R., Russell K.J., et al. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med 1997, 156(1):240-247.
108. Ohnishi K., Takagi M., Kurokawa Y., et al. Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest 1998, 78(9):1077-1087.
109. Hautamaki R.D., Kobayashi D.K., Senior R.M., et al. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997, 277(5334):2002-2004.
110. Turato G., Di Stefano A., Maestrelli P., et al. Effect of smoking cessation on airway inflammation in chronic bronchitis. Am J Respir Crit Care Med 1995, 152(4 Pt 1):1262-1267.
111. Rutgers S.R., Postma D.S., Ten Hacken N.H., et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000, 55(1):12-18.
112. Retamales I., Elliott W.M., Meshi B., et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001, 164(3):469-473.
113. Van Parijs L., Abbas A.K. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 1998, 280(5361):243-248.
114. Albert L.J., Inman R.D. Molecular mimicry and autoimmunity. N Engl J Med 1999, 341(27):2068-2074.
115. Davidson A., Diamond B. Autoimmune diseases. N Engl J Med 2001, 345(5):340-350.
116. Hutchinson D., Moots R. Coffee consumption, RF, and the risk of RA. Ann Rheum Dis 2001, 60(5):540-541.
117. Toivanen P. From reactive arthritis to rheumatoid arthritis. J Autoimmun 2001, 16(3):369-371.
118. Lee S.H., Goswami S., Grudo A., et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007, 13(5):567-569.
119. Greene C.M., Low T.B., O'Neill S.J., et al. Anti-proline-glycine-proline or antielastin autoantibodies are not evident in chronic inflammatory lung disease. Am J Respir Crit Care Med 2010, 181(1):31-35.
120. Wood A.M., de Pablo P., Buckley C.D., et al. Smoke exposure as a determinant of autoantibody titre in alpha-antitrypsin deficiency and COPD. Eur Respir J 2011, 37(1):32-38.
121. Pillai S.G., Ge D., Zhu G., et al. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet 2009, 5(3):e1000421.
122. Caulfield M.P., Birdsall N.J. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998, 50:279-290.
123. Wessler I., Kirkpatrick C.J., Racke K. Non-neuronal acetylcholine, a locally acting molecule, widely distributed in biological systems: expression and function in humans. Pharmacol Ther 1998, 77(1):59-79.
124. Joos L., He J.Q., Shepherdson M.B., et al. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet 2002, 11(5):569-576.